1. |
Influence of MS subtypes on response to treatment |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
DNA topoisomerase II inhibitors: new approaches to antitumour therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
HAART reduces hospitalisation, increases use of outpatient care |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Formoterol cost effective for paediatric asthma in the UK |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Ezetimibe enhances efficacy of statins in hypercholesterolaemia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 7-9
Raewyn Poole,
Preview
|
|
摘要:
Ezetimibe ['Zetia'], a novel cholesterol absorption inhibitor, is well tolerated and provides additional benefit to statin therapy in patients with primary hypercholesterolaemia, according to results from five studies presented at the XIVth World Congress of Cardiology (WCC) [Sydney, Australia; May 2002]. Coadministration of ezetimibe and statins resulted in significant reductions in LDL-cholesterol and triglyceride levels, and increases in HDL-cholesterol levels, compared with statin monotherapy. In one study, the addition of ezetimibe to patients' existing statin regimens had a significantly greater effect on lipid levels than placebo. Four parallel studies evaluating the effects of ezetimibe and/or various doses of a statin (lovastatin, pravastatin, simvastatin and atorvastatin, respectively) showed that the combination of the two agents was consistently more effective than monotherapy with either agent. Combination therapy with ezetimibe provided comparable LDL-cholesterol reductions at lower statin doses, compared with statin monotherapy, in all four studies; this is likely to be of significant benefit to patients because of the reduced potential for statin-related toxicity at lower doses.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Perindopril effective in 'real world' setting |
|
Inpharma Weekly,
Volume &NA;,
Issue 1341,
2002,
Page 13-15
Raewyn Poole,
Preview
|
|
摘要:
The long-acting ACE inhibitor, perindopril ['Aceon'], is effective in the treatment of mild-to-moderate hypertension, according to results from the open-label Aceon Community Trial (ACT) presented at the 17th Annual Scientific Meeting of the American Society of Hypertension [New York, US; May 2002]. Significant reductions in BP were achieved in the majority of patients treated with perindopril 4mg after 6 weeks; in the remainder of patients, BP was reduced by titration of the dose to 8mg. Overall, sitting systolic BP (SBP) and diastolic BP (DBP) were reduced by a mean of 17.5 and 10.7mm Hg, respectively. Subgroup analysis of data from this study showed that perindopril had comparable efficacy to that observed in the general population in elderly and African-American patients, and those who were receiving oral antihyperglycaemic agents for the treatment of diabetes mellitus.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|